AFP and hepatocellular carcinoma: Alpha-fetoprotein (AFP) has been extensively investigated as a biomarker for HCC detection; however, due to its suboptimal performance in terms of sensitivity (Se) (AFP-negative HCCs) [10], and its poor specificity (Sp) [11], there is no consensus on the use of AFP for the surveillance of patients who are at risk of developing HCC.